Thermo Fisher Scientific Inc. (NYSE:TMO) is New South Capital Management Inc.'s 6th Largest Position

New South Capital Management Inc. lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 155,845 shares of the medical research company's stock after selling 2,751 shares during the quarter. Thermo Fisher Scientific accounts for 3.9% of New South Capital Management Inc.'s holdings, making the stock its 6th biggest position. New South Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $96,401,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Ashton Thomas Private Wealth LLC boosted its holdings in shares of Thermo Fisher Scientific by 2.8% during the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 8,458 shares of the medical research company's stock worth $5,232,000 after buying an additional 233 shares during the period. Proactive Wealth Strategies LLC acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth $453,000. Meridian Management Co. boosted its holdings in shares of Thermo Fisher Scientific by 1.7% during the 3rd quarter. Meridian Management Co. now owns 5,703 shares of the medical research company's stock valued at $3,528,000 after acquiring an additional 93 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in Thermo Fisher Scientific by 1.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,104,441 shares of the medical research company's stock worth $683,174,000 after buying an additional 18,160 shares during the period. Finally, Iyo Bank Ltd. raised its position in shares of Thermo Fisher Scientific by 20.3% during the third quarter. Iyo Bank Ltd. now owns 10,909 shares of the medical research company's stock worth $6,748,000 after acquiring an additional 1,840 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 9,000 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the completion of the sale, the chief executive officer now owns 14,608 shares in the company, valued at approximately $8,076,178.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares of the company's stock, valued at $67,175,513.68. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 9,000 shares of the firm's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the transaction, the chief executive officer now directly owns 14,608 shares of the company's stock, valued at $8,076,178.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 37,150 shares of company stock valued at $20,651,865. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 1.2 %

Shares of NYSE TMO traded down $6.29 during mid-day trading on Tuesday, hitting $540.63. The company had a trading volume of 1,723,815 shares, compared to its average volume of 1,462,758. Thermo Fisher Scientific Inc. has a one year low of $439.11 and a one year high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a 50-day simple moving average of $592.59 and a two-hundred day simple moving average of $583.56. The company has a market capitalization of $206.79 billion, a PE ratio of 34.29, a price-to-earnings-growth ratio of 3.65 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion for the quarter, compared to analysts' expectations of $10.63 billion. During the same quarter in the previous year, the firm posted $5.69 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up .2% on a year-over-year basis. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a dividend of $0.39 per share. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific's payout ratio is 9.78%.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research analyst reports. UBS Group raised shares of Thermo Fisher Scientific to a "strong-buy" rating in a research report on Monday, September 16th. Redburn Atlantic initiated coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a "buy" rating and a $680.00 target price on the stock. Evercore ISI lowered their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Royal Bank of Canada lowered their price objective on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Finally, JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a research note on Friday, September 20th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $649.33.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.